DOCSLIB.ORG

Canadian Asset Map for Stem Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CANADIAN ASSET MAP FOR STEM CELL AND REGENERATIVE MEDICINE This publication is also available online in HTML and .pdf formats at www.ic.gc.ca/stemcells This publication is available upon request in accessible formats. Contact: Multimedia Services Section Communications and Marketing Branch Industry Canada Room 441E, East Tower 235 Queen Street Ottawa ON K1A 0H5 Telephone: 613-995-8552 Fax: 613-954-6436 Email: [email protected] Aussi offert en français sous le titre : Carte des ressources canadiennes dans les domaines des cellules souches et de la médecine régénérative Cette publication est disponible en ligne en formats HTML et pdf à www.ic.gc.ca/cellulessouches Release Note: Published by Industry Canada, March 2012. To obtain an electronic copy of this report, please visit www.ic.gc.ca/stemcells PERMISSION TO REPRODUCE: Non-commercial Reproduction Except as otherwise specifically noted, the information in this publication may be reproduced, in part or in whole and by any means, without change or further permission for non-commercial re-distribution, provided that due diligence is exercised in ensuring the accuracy of the information reproduced; that International BioPharma Solutions Ltd. is identified as the source; and that the reproduction is not represented as an official version of the information reproduced, nor as having been made in affiliation with, or with the endorsement of Industry Canada or International BioPharma Solutions Ltd. Commercial Reproduction Reproduction of materials in this document, in whole or in part, for the purposes of commercial redistribution is prohibited except with written permission from International BioPharma Solutions Ltd. For permission to reproduce the information in this publication for commercial redistribution, please contact : International BioPharma Solutions Ltd. 1277 Nelson Street, Suite 1502 Vancouver, BC, V6E 4M8 Canada Telephone: 604-408-4310 Fax: 604-408-4312 Internet: www.BioPharmaSolutions.com DISCLAIMER: This report was produced by International BioPharma Solutions Ltd. under contract for Industry Canada. The contents of the report are those of the report’s author, International BioPharma Solutions Ltd., and do not necessarily reflect the views of Industry Canada or the Government of Canada. NOTE TO READERS: This study was completed in March 2011, and the majority of the research was conducted between December 2010 and January 2011. The data and information contained in this report are believed to be reliable and accurate as of December 2010 to January 2011 but are not guaranteed for completeness or accuracy. Design and Pre-press production by: AN Design Communications Ottawa, ON www.an-design.ca TABLE OF CONTENTS3 1 EXECUTIVE SUMMARY 2 2 INTRODUCTION 4 2.1 Importance of Regenerative Medicine and Stem Cells 4 2.2 Purpose of the Asset Map 4 2.3 Description of Stem Cells 5 3 OVERVIEW OF STEM CELL AND REGENERATIVE MEDICINE RESEARCH IN CANADA 7 3.1 Canada’s Global Position in Stem Cell and Regenerative Medicine Research 7 3.2 Funding for Stem Cell and Regenerative Medicine Research 8 3.3 Stem Cell and Regenerative Medicine Research Centres 9 3.4 Funding and Researchers by University and Province 9 4 FOCUS OF STEM CELL AND TISSUE ENGINEERING RESEARCHERS 13 4.1 Pluripotent Stem Cells 13 4.2 Tissue-Specific Stem Cells (Somatic) 14 4.3 Cancer Stem Cells 15 4.4 Tissue Engineering 15 5 DISEASES/CONDITIONS TARGETED BY STEM CELL AND REGENERATIVE MEDICINE RESEARCHERS 19 5.1 Cancer 19 5.2 Neurology 19 5.3 Musculoskeletal 20 5.4 Cardiovascular 20 5.5 Metabolic Including Diabetes 20 5.6 Hematological 21 5.7 Other 21 5.8 Translational Medicine 21 6 RELEVANT SUPPORT FACILITIES 25 6.1 Biobanks 25 6.2 Other Relevant Facilities 25 7 NETWORKS 31 7.1 National and International Networks 31 7.2 Provincial Networks 31 8 KEY RESEARCHERS AND INSTITUTIONS 37 8.1 Key Researchers 37 8.2 Key Research Institutions 39 9 CONCLUSION 46 10 ACKNOWLEDGEMENTS 46 11 CONTACTS 47 iii CANADIAN ASSET MAP FOR STEM CELL TABLEAND REGENERATIVE OF CONTENTS MEDICINE APPENDIX 48 Appendix 1 Methodology 48 Appendix 2 Interviewees 51 Appendix 3 Lists of Canadian Stem Cells and Regenerative Medicine Researchers 52 3a. Researchers in Alphabetical Order 52 3b. Researchers According to Regenerative Medicine Focus 96 3c. Researchers According to Disease Focus 117 3d. Examples of Researchers Working in Translational Medicine and/or Clinical Trials 135 Appendix 4 Research Centres Listed by Province 137 Appendix 5 References and Notes 141 iv CANADIAN ASSET MAP FOR STEM CELL AND REGENERATIVE MEDICINE Prepared by International BioPharma Solutions Ltd. For the Life Science Industries Branch of Industry Canada CANADIAN ASSET MAP FOR STEM CELL AND REGENERATIVE MEDICINE EXECUTIVE SUMMARY • Regenerative medicine, particularly stem (9% each) cells, has considerable potential to help in • 416 researchers (in professor, associate the treatment of numerous common and professor, or similar positions) were intractable diseases and conditions identifi ed as working in the fi eld of stem • Canada is a leader in stem cell research cells and regenerative medicine research; as these cells were fi rst discovered by 47% of these are located in Ontario, 25% Canadian scientists; however, other in Quebec, 13% in British Columbia and countries have become more and more 9% in Alberta important in this fi eld • In terms of universities, the University • 68 centres within or affi liated with 25 of Toronto (or its affi liated institutions) of Canada’s universities are associated houses by far the greatest number of with stem cell and regenerative medicine researchers (26%), followed by the research University of British Columbia (UBC) • From the sources available for this Asset (12%), the University of Ottawa, McGill Map (mainly federal government), University, and Université de Montréal more than $277.5 million was spent on • Many of the 416 researchers are stem cell and regenerative medicine extremely well regarded, with 81 research over the last fi ve years (2006/7– endowed Chairholders, 69 of whom 2010/11), with Canadian Institutes of are Canada Research Chairs (CRCs); Health Research (CIHR) and Canada 20 researchers have made signifi cant Foundation for Innovation (CFI) as the contributions to stem cell research and/or largest funders (providing 36% and 23% are particularly well funded and/or cited of funds, respectively); since the data • Th e most important research from these sources perhaps account organizations within or affi liated with for only 50%–60% of overall funding, the universities in terms of numbers approximately $460 million–$560 million of stem cell and regenerative medicine were probably spent on stem cell/ researchers and endowed Chairs are regenerative medicine research with the University of Toronto (Ontario • Th e majority (65%) of funding went to Cancer Institute, Sick Kids, McEwen Ontario (ON), particularly the University Centre, Sunnybrook), the University of of Toronto and the University of Ottawa; British Columbia (Terry Fox Laboratory), Québec (QC) received 15%, followed by Université Laval (Laboratoire British Columbia (BC) and Alberta (AB) d’organogénèse expérimentale—LOEX), 2 EXECUTIVE SUMMARY 1 and the University of Ottawa (Sprott • Canada has at least 4 public or university Centre) cord blood banks, 2 stem cell line banks, • 73% of researchers work with stem and 15 other relevant tissue banks that cells of some type, while 19% work in can be accessed by its regenerative tissue engineering; others work in social medicine researchers; it also has at least sciences & humanities, bioprocessing, 3 stem cell bioprocessing/manufacturing or various stem cell technologies such facilities as well as other relevant shared as high throughput sorting/analysis or infrastructure cryopreservation • Canada’s stem cell and regenerative • Within the stem cell research area, 54% of medicine researchers are members of researchers work with tissue-specifi c stem at least 5 international, 6 national, and cells, 16% with pluripotent stem cells and numerous provincial relevant networks 10% with cancer stem cells; another 10% • Overall, Canada remains among the work with a number of stem cell types, world leaders in stem cell research. with the majority working with both tissue-specifi c and pluripotent • Of the researchers who only work with tissue-specifi c stem cells, 36% work with hematopoietic, 19% with bone marrow/ mesenchymal and 14% with neural cells • Of those who work with pluripotent stem cells, 92% work with embryonic and 20% with induced pluripotent stem cells (some researchers work with both types of pluripotent stem cells) • Within the tissue engineering fi eld, at least 65% work with both scaff olds and cells, while 27% work just with biomaterials; the focus of the other researchers was unspecifi ed • In terms of disease focus, 25% work in two or more disease areas, 24% work just on cancer, and 14% on neurological, 12% on musculoskeletal, and 10% on cardiovascular conditions • Perhaps 100 researchers (24%) are involved in the translation of stem cell research from the laboratory to the clinic, with the Stem Cell Network (SCN) so far devoting approximately $50 million to the funding of translational projects over the past 10 years 3 CANADIAN ASSET MAP FOR STEM CELL AND REGENERATIVE MEDICINE INTRODUCTION 2.1 Importance of Regenerative in wound healing. However, these clinical Medicine and Stem Cell uses represent just a small fraction of the Regenerative medicine involves the renewal opportunities in regenerative medicine of body tissues or the restoration of organ and researchers are working furiously to and tissue function through the use of understand the role stem cells may play living cells, particularly stem cells. Stem in other diseases, and to translate these cells off er a particularly rich source of findings into the clinic. regenerative technologies as, under the right conditions, they can diff erentiate To be clinically effective, stem cells need into many diff erent cell types (see below). to be delivered to and integrate with the Th ey have considerable potential to help relevant body site.
Recommended publications
  • Universidad Autónoma De Madrid

    Universidad Autónoma De Madrid

    UNIVERSIDAD AUTÓNOMA DE MADRID DEPARTAMENTO DE BIOLOGÍA MOLECULAR Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Madrid, 2015 DEPARTAMENTO DE BIOLOGÍA MOLECULAR FACULTAD DE CIENCIAS UNIVERSIDAD AUTÓNOMA DE MADRID Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Licenciatura en Biología Molecular y Fisiología Director de Tesis: Prof. Christopher Heeschen, M.D. PhD Centro de células madre en el cáncer y el envejecimiento Barts Instituto de Cancer (BCI) This thesis, submitted for the degree of Doctor of Philosophy at the Universidad Autónoma de Madrid, has been completed in the Stem Cells & Cancer Group at the Spanish National Cancer Research Centre (CNIO) and Centre for Stem Cells in Cancer and Ageing, Barts Cancer Instutute (BCI) under the supervision of Prof. Dr. Christopher Heeschen. Dedicated to my parents, my sister Ivana and my friends who always supported me. ACKNOWLEDGEMENTS It is strange to look back in time and see myself entering true the door of CNIO my first day in Christopher’s laboratory back in October 2010. For some maybe little and for other’s so much. Thank you Christopher for replaying to my email and opening me the door of your lab! It was just a start of an incredible journey that led me where I am now, and that will mark my next trails to run. So many people I need to mention and say thanks for their unconditional help and support. Enza thank you for accepting me as your student and for being patient with me. I will never forget how you would always tell me to think why I am doing things.
  • University of Toronto University-Wide Impact Presentation

    University of Toronto University-Wide Impact Presentation

    UNIVERSITY OF TORONTO UNIVERSITY-WIDE IMPACT PRESENTATION INTRO: .......................................................................................... 2 SECTION 1: GLOBAL FOOTPRINT .............................................. 3 SECTION 2: INNOVATION AND IMPACT .................................... 15 SECTION 3: EXCELLENCE AND LEADERSHIP IN SOCIETY ..... 31 Text is not editable on animation slides. Updated May 2021 ON-SCREEN IMAGE SPEAKER’S NOTES BEGINNING OF PRESENTATION [Good afternoon]. My name is [X], and I serve as [X] at the University of Toronto. Thank you for joining us [today]. [Today] I would like to take you through a presentation that speaks to the crucial role that U of T is honoured to play in our communities and our world. U of T is a world-leading university with three campuses in the Greater Toronto Area. We provide students with a comprehensive global education, produce life-changing research, and promote economic growth and social progress in our communities. I’m going to cover three aspects: • U of T’s Global Footprint • U of T’s Innovation and Impact • U of T’s Excellence and Leadership in Society Since its very early days, U of T has been fortunate to have forged connections with institutions around the world and to have welcomed faculty and students from elsewhere to become part of the U of T community. Today, U of T’s global footprint is significant. 2 SECTION 1 GLOBAL FOOTPRINT 3 ON-SCREEN IMAGE SPEAKER’S NOTES We are immensely proud of our worldwide alumni community. Over 630,000 U of T alumni live, work and contribute to civil society in more than 190 countries and territories. Few universities in the world can rival the cultural diversity of our student population.
  • Radiation Medicine Program

    Radiation Medicine Program

    Radiation Medicine Program ANNUAL 2020 REPORT 2021 VALUES MISSION Innovation Advance exemplary radiation Excellence medicine through patient Collaboration care, research & education Accountability in partnership with CONTENTS Integrity our patients & community 4 A Message from the Chief 6 Program Overview 7 2020: The Year in Numbers 8 Strategic Roadmap to 2026 VISION 10 Clinical Care CURE EVOLVE 15 Quality & Safety Predictive Health & Precision Radiation Medicine. Advanced Particle Adaptive Radiotherapy Therapy & Theranostics 18 Education Personalized Care. 21 Research Global Impact. 26 Team RMP COMFORT & CONNECT Systems to Maximize CONFIDENCE Innovation & Wellbeing Technology-enabled Patient Experience Transformation A MESSAGE FROM THE CHIEF The Radiation Medicine Program (RMP) at the Princess Margaret Cancer Centre is committed to delivering the highest standard of patient care. Over the RMP’s innovative education programs continue to thrive and attract a diverse group of national and international attendees. Our award-winning Accelerated past year, our dynamic multidisciplinary team of radiation oncologists, medical physicists, radiation therapists, administrators, and support staff have worked Education Program (AEP) demonstrated extraordinary resourcefulness this past year, standing strong amidst the pandemic, and continuing to provide top- together to advance our vision of “Precision Radiation Medicine. Personalized Care. Global Impact.” RMP continues to uphold our foundational values of level education to a broad spectrum of learners.
  • Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund

    Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund

    A Pre-Budget Submission to the House of Commons Standing Committee on Finance To Implement the Canadian Stem Cell Strategy By Establishing The Till & McCulloch Medicines of Tomorrow Innovation Fund James Price President & CEO Canadian Stem Cell Foundation February 9, 2016 EXECUTIVE SUMMARY Stem cells represent the biggest innovation in medicine of the last half century. These cells have the power to cure many diseases for which current medical practice can only provide symptomatic relief and chronic care – a reality that is straining health care systems in Canada and in countries around the globe. Stem cells are a hallmark of Canadian innovation. They were first discovered in Canada and Canada is one of the top three countries in stem cell R&D, with our scientists ranking among the best in the world. Recent investments, such as the Government’s $20-million commitment to establish a cell-manufacturing facility in Toronto and the $114-million Medicine By Design grant for the University of Toronto, will help Canada move forward. However, major commitments by competitor jurisdictions – most notably California, with its investment of $3 billion, and Japan, with an investment of $1 billion in stem cells and regenerative medicine -- challenge Canada’s leadership in this sector of the knowledge economy. Moreover, Canada lacks a national plan to succeed in the coming cell therapy and regenerative medicine boom. The Canadian Stem Cell Strategy -- created in consultation with 150 scientists, medical doctors, leaders from major health charities, industry experts, investors and philanthropists – will: • deliver up to 10 new curative therapies within 10 years; • transform health care and ease the strain on the health system; and • attract private investment and generate 12,000 jobs for Canadians.
  • News Release

    News Release

    NEWS RELEASE: June 14, 2005 Health care leaders create Canada’s first national health advisory body The Canadian Academy of Health Sciences will give Government and the public comprehensive expertise and advice on health issues EDMONTON - When the President of the United States wants advice on a public health issue, he calls the United States’ National Academies. When the Prime Minister of Great Britain wants to seek similar counsel, he usually turns to the Royal Society of Britain. But when the Prime Minister of Canada wants similar advice, who does he call? Well, that’s not always entirely clear, given the more narrowly defined mandates of many Canadian organizations. Now, however, owing to a recent initiative by a group of leading health care leaders and researchers, the Prime Minister will be able to call the Canadian Academy of Health Sciences (CAHS), recently created to: • Develop informed, strategic assessments on urgent health issues; • Inform public policy on these issues; • Enhance Canada’s readiness to deal with global health issues; and, • Provide a recognized and authoritative Canadian health science voice internationally. According to one of the Academy’s key organizers, the establishment of the Academy is long over due—and all the more pressing given the potential global health threats to Canadians, most recently exemplified by the SARS threat. “Ask Canadians what they care about most, and they answer unequivocally: ‘health,’” explains University of Alberta Professor of Medicine Paul Armstrong, CAHS’s first president. “It makes sense, therefore, that Canada should have an organization that government—and Canadians—can turn to for sound, impartial advice and research on pressing health issues.” The organization will also have an international role to play, representing Canada’s interests abroad and working closely with other nations’ parallel agencies.
  • By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership

    BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie
  • Printable List of Laureates

    Printable List of Laureates

    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
  • Prospectus for a Major Assessment: the Return on Investments in Health Research

    Prospectus for a Major Assessment: the Return on Investments in Health Research

    Prospectus for a Major Assessment: The Return on Investments in Health Research: Defining the Best Metrics Prepared by the Canadian Academy of Health Sciences May 2007 WO The Return on Investments in Canadian Health Research – The Situation Investments in health research have increased significantly across Canada over the past decade. Naturally, and justifiably, with these greater investments come increased expectations. In addition, the widening diversity of stakeholders engaged in and/or supporting health research has led to a broader range of anticipated outcomes. These expectations include: 1] better health; 2] greater life expectancy; 3] translation of research findings into improvements in quality of life; 4] informed public policy on health related issues across the full spectrum of government and private sector activity; 5] new commercial opportunities within and beyond Canadian borders; 6] increased attraction of the next generation to pursue careers in health research and the health sector; 7] a better ‘state of readiness” for the unexpected threats to health that inevitably develop in the contemporary world. In parallel with these expectations, a confluence of factors has placed intense focus on understanding what return our society receives for the investments made in health research. Some of these include: • lack of public understanding of the value of research and its applicability to current issues in health care at a time of unsurpassed concern about accessible, affordable, high quality health care in a publicly funded
  • 8 Montarville (De) 1 469 717 2 764 1 472 481 Montréal-Nord Et Tremblay Inc

    8 Montarville (De) 1 469 717 2 764 1 472 481 Montréal-Nord Et Tremblay Inc

    gouvernement du Québec comptes publics année financière terminée le 31 mars 1987 dl O □ volume 2 détail des dépenses • fournisseurs et bénéficiaires • biens en capital Publiés conformément aux dispositions de l’article 71 de la Loi sur l’adm inistration (L.R.Q., c.A-6) Mfrîfcîcra dss Finanças Gouvernement du Québec Ministère des Finances Date: -•> \ " ; ü ; ISSN 0706-2869 ISBN 2-550-17824-6 (Édition complète) ISBN 2-550-17826-2 (Volume 2) Dépôt légal — 4e trimestre 1987 Bibliothèque nationale du Québec TABLE DES MATIERES SECTION LISTE DES FOURNISSEURS ET BÉNÉFICIAIRES 1 LISTE DES BIENS EN CAPITAL 2 1-1 SECTION 1 LISTE DES FOURNISSEURS ET BÉNÉFICIAIRES Pour chaque catégorie de dépenses, sauf « Dépenses de trans­ NOTE fert», la liste des fournisseurs et bénéficiaires est émise au niveau du ministère selon les limites et critères de publication suivants: a) Traitements, salaires, allocations et autres rémunérations: Ne sont pas détaillées au i wm des fournisseurs et bénéficiaires les sommes — Ministres, sous-ministres et hauts fonctionnaires de rang équi­ ayant été versées à «Oiverses personnes» à savoir: valent: tout montant; Allocations aux propriétaires de forêts privées dans le cadre des intérêts sur — Personnel cadre (administrateurs, directeurs de cabinet et leurs emprunts auprès du crédit forestier (Office du crédit agricole du Qué­ fonctionnaires de rang équivalent): tout montant; bec) et aux agriculteurs dans le cadre des intérêts sur leurs emprunts auprès — Toute allocation: 11 000 $ et plus; de l'Office du crédit agricole du Québec, du crédit agricole par les institu­ — Contributions de l’employeur: 22 000 $ et plus. tions privées, de l’amélioration des fermes, du crédit à la production, du cré­ dit spécial, du prêt agricole (Société du crédit agricole du Canada), de la b) Autres catégories: 22 000 $ et plus, sauf le Service de la dette mise en valeur des exploitations agricoles, du réaménagement foncier et dont le détail n’est pas publié.
  • Health Matters

    Health Matters

    Canadian Academy of Health Sciences Académie canadienne des sciences de la santé health matters the online newsletter JANUARY 2013 | VOLUME 2, ISSUE 2 of the Canadian Academy of Health Sciences/Académie canadienne des sciences de la santé President’s Message The 2012 Henry G. Friesen International For most of you, you are halfway through another academic year with winter terms just about Prize Lecture Delivered to start – you have submitted one or more grant applications and Dr. Marc Tessier-Lavigne, President, are well along with teaching commitments. At CAHS we had a Rockefeller University, the 2012 Henry G. very successful annual meeting. Our Forum on END OF LIFE was Friesen International Prize winner, presented excellent thanks to the expertise of the speakers and to the hard a luncheon address to the Canadian work of organizers Drs. Deborah Cook, Paul Armstrong, John Cairns Academy of Health Sciences entitled “Brain and Jay Kalra. We are now in the process of deciding our next steps. Development and Brain Degeneration: We like to continue on to an Assessment based on the Forum but Molecular Control of Nerve Growth and in this instance the Board and the organizers are recommending Pruning” on Thursday, September 20, 2012. a different approach. A key message from the Forum was the lack of information readily available to the public about End of Life issues. With this in mind, we are working on an article from the Forum to be published in the CMAJ; a summary of proceedings of the symposium to be published in a peer-reviewed journal; and a Dr.
  • 2011/2012 Annual Report

    2011/2012 Annual Report

    BUILDINGALEGACY Stem Cell Network 2011-2012 Annual Report StemCell Network 2011-2012 Annual Report TABLE OF CONTENTS Directors’ Message .........................................................................................2 Bridging The Translational Gap ...................................................................4 In Profile: Dr. Denis-Claude Roy .............................................7 The High-Throughput Revolution................................................................8 In Profile: Dr. Aaron Schimmer .........................................11 See The Potential: An Industry-Academia Hybrid ...............................12 In Profile: Dr. Corinne Hoesli ..............................................14 A Research Conference Built by the Community .................................15 In Profile: Dr. Peter Zandstra .............................................17 Building an Informed Public.......................................................................18 In Profile: Angela McDonald .............................................21 Network Community ...................................................................................22 2011-12 Financial Statements ...................................................................25 Directors’ Message Message from SCN’s Board Chair, Scientific Director, and Executive Director t’s year 12. On paper, the Stem Cell Network has entered its for blood cancers at the University of Montréal. Dr. Roy’s project, sunset years, but we’re not ready to rest on our laurels
  • Building on Canada's Strengths in Regenerative Medicine

    Building on Canada's Strengths in Regenerative Medicine

    BUILDING ON CANADA’S STRENGTHS IN REGENERATIVE MEDICINE Workshop Report Science Advice in the Public Interest BUILDING ON CANADA’s STRENGTHS IN REGENERATIVE MEDICINE Workshop Report ii Building on Canada’s Strengths in Regenerative Medicine THE COUNCIL OF CANADIAN ACADEMIES 180 Elgin Street, Suite 1401, Ottawa, ON, Canada K2P 2K3 Notice: The project that is the subject of this report was undertaken with the approval of the Board of Governors of the Council of Canadian Academies (CCA). Board members are drawn from the Royal Society of Canada (RSC), the Canadian Academy of Engineering (CAE), and the Canadian Academy of Health Sciences (CAHS), as well as from the general public. The Steering Committee and workshop participants responsible for the report were selected by the CCA for their special competencies and with regard for appropriate balance. This workshop report was prepared for the Government of Canada in response to a request from the Minister of Innovation, Science and Economic Development Canada. Any opinions, findings, or conclusions expressed in this publication are those of the authors, the Steering Committee of the Workshop on the Opportunities and Challenges for Regenerative Medicine in Canada and do not necessarily represent the views of their organizations of affiliation or employment, or the sponsoring organization, Innovation, Science and Economic Development Canada. Library and Archives Canada Cataloguing in Publication Workshop on Opportunities and Challenges for Regenerative Medicine in Canada (2016 : Toronto, Ont.) Building on Canada’s strengths in regenerative medicine : workshop report / Workshop on Opportunities and Challenges for Regenerative Medicine in Canada. Issued also in French under title: Mettre à profit les forces du Canada en médecine régénérative.